Roche Sees Pegasys Approval Delay Until 2002, But With Broader Indication
Executive Summary
Roche's "current expectation" for the pegylated interferon product Pegasys is that it will be approved in the first half of 2002, with an indication covering both monotherapy and combination use.
You may also be interested in...
Pegasys Individualized Dosing To Be Studied As EU Postmarket Commitment
Roche will study individualized dosing regimens for Pegasys (peginterferon alfa-2a) in combination with ribavirin as part of its postmarketing commitments in Europe
Pegasys Individualized Dosing To Be Studied As EU Postmarket Commitment
Roche will study individualized dosing regimens for Pegasys (peginterferon alfa-2a) in combination with ribavirin as part of its postmarketing commitments in Europe
Xenical Diabetes sNDA Withdrawn; FDA, Roche Disagree On Wording
Roche is contemplating how to pursue a type 2 diabetes indication for Xenical after withdrawing a supplemental NDA for the claim